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HLA-G expression deﬁnes a novel regulatory T-cell subset present in human
peripheral blood and sites of inﬂammation
Ute Feger,1 Eva Tolosa,1 Yu-Hwa Huang,2 Anne Waschbisch,2 Tilo Biedermann,3 Arthur Melms,1 and Heinz Wiendl1,2
1Department of General Neurology, Hertie-Institute for Clinical Brain Research, Eberhard-Karls-University Tuebingen, Tuebingen; 2Clinical Research Group for
Multiple Sclerosis and Neuroimmunology, Department of Neurology, University of Wuerzburg, Julius-Maximilians-University Wuerzburg, Wuerzburg;
3Department of Dermatology, Eberhard-Karls-University Tuebingen, Tuebingen, Germany
Regulatory T cells can inhibit harmful
immunopathologic responses directed
against self and foreign antigens and play
a major role in controlling autoimmunity.
Herewehaveidentiﬁedandcharacterized
a subpopulation of CD4 and CD8 T cells in
human peripheral blood expressing the
immune tolerizing molecule HLA-G. HLA-
G–expressing T cells are hypoprolifera-
tive, are CD25- and FOXP3-negative, and
exhibitpotentsuppressivepropertiesthat
are partially mediated by HLA-G. HLA-G–
positive (HLA-Gpos) T cells are found at
low percentages among CD4 and CD8
single-positive thymocytes, suggesting a
thymic origin. The presence of HLA-Gpos
T cells at sites of inﬂammation such as
inﬂamed skeletal muscle in myositis or
the cerebrospinal ﬂuid of patients with
acute neuroinﬂammatory disorders sug-
gests an important function in modulat-
ingparenchymalinﬂammatoryresponses
in vivo. (Blood. 2007;110:568-577)
© 2007 by TheAmerican Society of Hematology
Introduction
The immune system must distinguish between self and nonself struc-
tures, but also between harmful and innocuous foreign antigens to
prevent nonessential and self-destructive immune responses. Compel-
ling evidence indicates that regulatory T cells play an important role in
the maintenance of immune tolerance under nonpathologic as well as
under pathologic conditions.1-3 Several subsets of T lymphocytes with
the ability to down-regulate the proliferation of effector cells have been
described in mice and humans. Different types of regulatory T cells can
bedifferentiatedbydistinctsuppressivemechanismsandbytheirorigin.
Naturally occurring CD4CD25 regulatory T cells (Tregs) exert their
suppressive effects via cell contact, although the nature of the involved
molecules is still elusive.4 The suppressive capacity of a second subset,
type1Tregulator(Tr1)cellsandTh3cells,iscontactindependentandis
based mainly on cytokines such as IL-10 and TGF-.5 It seems that
these cells, in contrast to the naturally occurring CD4CD25 Tregs,
represent altered states of differentiation rather than a unique cell
lineage. Furthermore, other T cells with suppressive activity include the
antigen-speciﬁc CD8CD286 and the TCR  double-negative
(CD4CD8)T-cell subsets.7
HLA-G is a HLA class Ib antigen characterized by a restricted
tissue expression, a low polymorphism, and 7 isoforms (HLA-G1
to -G7).8 HLA-G1 has a structure similar to that of classic HLA
class I molecules: a heavy chain noncovalently associated with
2-microglobulin and a nonameric peptide. Although capable of
acting as a peptide-presenting molecule, its strong immune-
inhibitory properties identify HLA-G as a mediator of immune
tolerance with speciﬁc relevance at immune-privileged sites such
as trophoblast or thymus: HLA-G inhibits allogeneic proliferation
of T cells,9-12 natural killer cell cytotoxicity,13-16 as well as
antigen-speciﬁc T-cell cytotoxicity.12,17-18 Its direct modulatory
function is mediated via 3 inhibitory receptors, ILT2  CD85j,
ILT4  CD85d, and KIR2DL4  CD158d.19-21 Ectopic expression
of HLA-G has been identiﬁed as one of the mechanisms used by
tumor cells to escape immune surveillance17,22-24 and to modulate
inﬂammation in autoimmune disorders.25-27 HLA-G molecules are
induced after allograft transplantation28-29 and during mixed lym-
phocyte reactions.11,30 Under such alloreactive conditions, T cells
are capable of secreting soluble HLA-G (sHLA-G), which sup-
presses alloproliferative responses.30 In nice agreement, soluble
HLA-G has been associated with the modulation of graft accep-
tance outcome.28-29 Expression of membrane-bound HLA-G
has also been described on T cells under conditions such as
after transplantation and in human immunodeﬁciency virus
(HIV)–infected patients.30-31
We report here that CD4 and CD8 T cells expressing HLA-G
are present in human peripheral blood under normal physiologic
conditions. These naturally occurring cells show potent suppres-
sive function, can be detected in the thymus and are different from
the naturally occurring CD4CD25 Tregs. We could detect these
cells in target organs of patients with neuroinﬂammatory disorders,
supporting the assumption of their role in modulating peripheral
inﬂammation in vivo.Altogether, our data provide evidence for the
identiﬁcation of a novel subset of naturally occurring regulatory
T cells characterized by cell surface expression of HLA-G.
Materials and methods
Blood, CSF, and thymus samples
Phenotypic and functional analysis of HLA-G on T cells was performed
with human peripheral blood obtained from healthy donors (n  28;
male-female  17:11; mean age, 31.5 years; range, 22-55 years). Paired
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16 male) referred to the Department of Neurology (University of
Wuerzburg) for diagnostic lumbar puncture. Fifteen patients with multiple
sclerosis (MS), 10 with other inﬂammatory neurologic diseases (OIND),
and 9 with noninﬂammatory neurologic diseases (NIND) (mean age, 47
years; range, 17-82 years; Table S1, available on the Blood website; see the
Supplemental Materials link at the top of the online article) were assessed
by ﬂow cytometry. Patients with MS were diagnosed according to criteria of
McDonald et al.32 Patients included in the study were without corticoste-
roids for at least 2 months. All patients gave informed consent in
accordance with the Declaration of Helsinki and a protocol approved by the
review boards of the University of Tuebingen and the University of
Wuerzburg. CSF (8-20 mL) was obtained by lumbar puncture from all
patients.At the same time, 10 mLperipheral blood was collected by venous
puncture.
Normal human thymus tissue was obtained from 6 infants (aged 14 days
to 12 months) undergoing corrective cardiac surgery following the institu-
tional review board guidelines of the university clinic of Tuebingen.
Preparation of peripheral blood mononuclear cells (PBMCs), isolation
of HLA-GposTcells, and generation of dendritic cells (DCs); antibodies and
ﬂow cytometry; and immunohistochemistry are described in Document S1.
In vitro culture of CD4 HLA-Gpos T cells
For assessing stability of HLA-G expression over time, CD4 HLA-Gpos and
HLA-Gneg T cells were cultured in standard culture medium, RPMI (Gibco,
Karlsruhe, Germany) with L-glutamine and 25 mM HEPES, 10% human
AB serum (PAA Laboratories, Linz, Austria); 20 g/mL gentamicin
(Biowhittaker, Verviers, Belgium); 100 IU/mL penicillin, 100 g/mL
streptomycin (Gibco); and 2 mM L-glutamine (Biowhittaker), for a period
of 3 days. HLA-G expression was assessed by ﬂow cytometry.
T-cell stimulation assays
We stimulated T cells or isolated CD4/8 HLA-Gpos and HLA-Gneg T-cell
subsets in standard culture medium with CD3/CD28 beads (Dynal, Oslo,
Norway) or glatirameracetate (GA; TEVA, Petach Tikwa, Israel). T-cell
proliferation was measured after 3 days in culture and an additional 16-hour
pulse with [3H] Tdr (18.5 kBq per well) using a liquid scintillation counter.
For allogeneic stimulation, freshly isolated T cells (whole CD4 T cells,
and CD4 HLA-Gpos/neg and CD8 HLA-Gpos/negTcells; 1–3  105 per well in
a 96-well plate; triplicates) were cultured in the presence of different
numbers of irradiated DCs or in a mix lymphocyte reaction (MLR) using a
mix of allogeneic PBMCs from 5 different healthy donors (donor mix). For
further information see Document S1.
Suppression assays
Lymphocyte proliferation of CD4 or CD8 T cells in the presence of
suppressor cells was assessed by ﬂow cytometry after CFDA-SE
labeling of the effector/responder lymphocytes. CD4 or CD8-effector/
responder cells (1  106) were incubated in 500 LPBS containing 10 M
CFDA-SE (carboxyﬂuorescein diacetate, succinimidyl ester; Molecular
Probes, Karlsruhe, Germany) and subsequently quenched with medium
containing 15% FCS.
To assess the suppressive nature of CD4 and CD8 HLA-Gpos T cells,
CFDA-SE–labeled CD4 or CD8 HLA-Gneg T cells (0.3-1 105 cells per well)
were stimulated in a physiologic manner with 1 g/mL soluble anti-CD3
(OKT3) in the presence of irradiated (33 Gray) allogeneic cells to provide
optimal costimulation, and with increasing numbers of CD4 or CD8 HLA-Gpos
T cells as indicated in the ﬁgure legends. We measured proliferation on day 4 by
ﬂow cytometry. Suppression was calculated after normalization of the values to a
maximumgivenbytheproliferationofCD4orCD8HLA-GnegTcellsalone.For
further information and a description of cytokine assays, see Document S1.
RNA extraction, cDNA synthesis, and quantitative
real-time PCR
Total RNA extraction and ﬁrst-strand cDNA synthesis were performed by
standard methods. Quantitative analysis of gene expression was performed
by reverse-transcription–polymerase chain reaction (RT-PCR) using the
ABI prism 7000 Sequence Detection System (Applied Biosystems, Foster
City, CA).33 cDNAtemplates were ampliﬁed for IFN-, IL-10, TGF-, and
18S using Sybr Green PCR Master Mix (Eurogentec, Cologne, Germany).
For Foxp3 and HLA-G, cDNAs were ampliﬁed using qPCR MasterMix
Plus (Eurogentec, Cologne, Germany) and a primer pair with probe kit
(MGB Probe; Applied Biosystems). Relative quantiﬁcation was performed
with the 2		Ct-method (Applied Biosystems user bulletin). Samples were
normalized to 18S rRNA to account for the variability in the initial
concentration of the total RNA and conversion efﬁciency of the reverse-
transcription reaction. For cytokine and FoxP3 expression of CD4 HLA-
Gpos and CD4 HLA-Gneg T cells mRNAfrom unstimulated PBMCs and for
the expression of HLA-G mRNA of JEG3 cells were used as calibrators.
Oligonucleotides used in this study are as follows: IFN- forward,
5
-TTCAGCTCTGCATCGTTTTG and IFN- reverse, 5
-CTTTCCAAT-
TCTTCAAAATGCC; IL-10 forward, 5
-GTT TTA CCT GGA GGA GGT
GAT and IL-10 reverse, 5
-GGC CTT GCT CTT GTT TTC AC; TGF-
forward, 5
-GCC CTG GAC ACC AAC TAT TG and TGF- reverse,
5
-CTG GTC CAG GCT CCAAAT; 18S forward, 5
-CGG CTACCACAT
CCAAGGAAand 18S reverse, 5
-GCT GGAATTACC GCG GCT.
Statistical analysis
For statistical analysis of the blood and CSF we used paired t tests. Each
paired t test was conducted for CD4 and CD8 HLA-Gpos frequencies in
NIND, OIND, and MS patients. For comparison of acute versus stable
disease, again paired t test was applied. The P values were calculated
2-tailed and in all cases considered statistically signiﬁcant if P was less
than .05.
Results
A subset of human CD4 and CD8 T cells in peripheral blood
expresses the nonclassic MHC molecule HLA-G
Recent data suggest that the expression and function of HLA-G are
broader than initially thought. We ﬁrst analyzed whether human
peripheral blood T cells express HLA-G under physiologic condi-
tions. Peripheral blood from healthy donors (ages 22 to 50 years)
was assessed for HLA-G1 expression on CD4 and CD8 T cells by
ﬂow cytometry using the monoclonal antibody (mAb) MEM-G9
(Figure 1A). Using mAb MEM/G9 we found that an average of
1.6% (range, 0.1%-8.3%; n  28) of CD4 T cells and 3.3% (range,
0.6-5.2%; n  24) of CD8 T cells express HLA-G on the cell
surface (HLA-Gpos T cells; Figure 1B). These ﬁndings were
conﬁrmed using another monoclonal antibody against HLA-G,
mAb 87G (data not shown). Neither expression levels nor fre-
quency of HLA-GposTcells correlated statistically with age and sex
in healthy donors (data not shown). Phenotypical analysis of
HLA-Gpos T cells showed a bias toward more naive (CD45RA,
CCR7) phenotype in CD8 HLA-Gpos T cells (69.3%  13.7%
naive T cells in CD8 HLA-Gpos versus 39.5%  1.7% naive T cells
in CD8 HLA-Gneg cells; n  5). CD4 HLA-Gpos T cells did not
differ in their CCR7/CD45RA distribution from their HLA-Gneg
counterparts (Figure S1). We next performed a detailed phenotypi-
cal analysis of HLA-Gpos T cells. No evidence of activation of the
HLA-Gpos subset was revealed by measuring the expression of
CD28, ICOS, PD-1, CTLA-4, CD40L (CD154), CD95, or the
alpha/beta TCR. The expression of CD31 (PECAM-1) was higher
in HLA-Gpos CD8 T cells (MFI CD8 HLA-Gneg  22.58  16.74,
mean MFI CD8 HLA-Gpos  26.34  17.30; P  .002), possibly
reﬂecting their more naive phenotype (Table S2; Figure S1). Flow
cytometric analysis of the TCR V chains did not show repertoire
differences between the HLA-Gpos T cells and their HLA-Gneg
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reﬂect populations with a skewed TCR (data not shown). Thus, we
identiﬁed a sizable population of HLA-G–expressing T cells both
in the CD4 and the CD8 population in the blood of healthy donors.
At ﬁrst glance, these cells show no other obvious phenotypic
differences than a more naive phenotype of CD8 HLA-Gpos T cells.
HLA-Gpos T cells show a reduced proliferation to allogeneic and
polyclonal stimuli
To investigate the functional properties of HLA-G–bearing T cells,
we established a multistep, magnetic bead–based puriﬁcation
protocol for CD4 HLA-Gpos and CD8 HLA-Gpos T cells. Brieﬂy,
CD4 or CD8 T cells are ﬁrst isolated by negative selection and
subsequently the HLA-Gpos cells are labeled with a biotinylated
anti–HLA-G antibody (MEM-G9) and pulled down using antibi-
otin magnetic beads (“Materials and methods”). In all cases, the
purity of the selected cells was between 60% and 95% (Figure 2A).
To assess stability of HLA-G cell surface expression, puriﬁed
subsets of CD4 HLA-Gpos and HLA-Gneg T cells were cultured ex
vivoandHLA-Gexpressionwasdeterminedbyserialﬂuorescence-
activated cell sorting (FACS) analysis. Percentages of HLA-G–
positive T cells were normalized to HLA-G expression of the ex
vivo population (set to 1). Levels of HLA-G expression did not
change signiﬁcantly over 72 hours in culture (Figure 2B). Stimula-
tion of HLA-G–negative T cells using anti-CD3/CD28 beads,
PHA, or anti-CD3 alone did not lead to an up-regulation of
HLA-G, therefore suggesting that cell surface HLA-G is a stable
phenotype rather than an inducible phenomenon (data not shown).
Of note, the initial drop of HLA-G observed at 24 hours is most
likely due the presence of the antibody used for bead separation in
the initial (ex vivo) sample.
Next, ex vivo isolated CD4 HLA-Gpos T cells were analyzed for
their capacity to proliferate to several stimuli. CD4 HLA-Gpos
T cells showed a reduced proliferation to allogeneic mature
dendritic cells (DCs) and to anti-CD3/CD28 beads compared with
the entire CD4 T-cell population or to their HLA-G–negative
counterparts (Figure 2C-D). In accordance to the CD4 subsets, we
also found a reduced proliferation of CD8 HLA-Gpos T cells to
polyclonal or allogeneic stimulus compared with CD8 HLA-Gneg T
cells (Figure S2A). Next, we assessed if this hypoproliferative
nature could be overcome by addition of IL-2 or repeated
stimulation (secondary stimulatory conditions). Therefore we ﬁrst
stimulated CD4 HLA-Gpos and HLA-Gneg T cells with mature DCs
in the absence or presence of exogenous IL-2. Although the
proliferation of CD4 HLA-Gneg T cells was increased by the
addition of IL-2, it had virtually no effects on the proliferation of
CD4 HLA-Gpos T cells (Figure 2E). Furthermore, we analyzed
the behavior of CD4 HLA-GposTcells in secondary proliferation
assays. After a ﬁrst round of allogeneic stimulation, cells were
restimulated with either the previous allogeneic stimulus or with
CD3/CD28 beads (Figure 2F). In both cases, CD4 HLA-Gpos T
cells remained resistant to the induction of proliferation, while CD4
HLA-Gnegcellswereresponsive.Verysimilarresultswereachieved
by a second, independent method measuring the proliferative
response by CFSE dilution (data not shown). These experiments
show that CD4 HLA-GposTcells are hypoproliferative and that this
low proliferative capacity cannot be overcome by addition of
exogenous IL-2 or by secondary stimulation.
Soluble factors produced by CD4 HLA-Gpos T cells
We next investigated the soluble factors produced by HLA-G–
expressing CD4 T cells in response to T-cell stimulation. To ensure
highest purity, HLA-Gpos and HLA-Gneg CD4 T cells were isolated
by cell sorting from prepuriﬁed CD3 T cells (Figure 3A). RT-PCR
analysis showed that CD4 HLA-Gpos T cells expressed high levels
of HLA-G mRNA, whereas their negative counterparts lacked
HLA-G transcripts, supporting again the concept of a speciﬁc
subset rather than transient surface expression (Figure 3B). Next,
we investigated the production of the soluble isoform HLA-G5.
Therefore, puriﬁed CD4 HLA-Gpos and CD4 HLA-Gneg T cells
were stimulated for 4 days with CD3/CD28 beads and after ﬁxation
stained intracellularly with the HLA-G5–speciﬁc antibody 5A6G7.
Almost all (98%) of the CD4 HLA-Gpos T cells were positive for
HLA-G5. Of note, 26% of the T cells lacking HLA-G1 on the
surface also expressed HLA-G5 intracellularly after stimulation
(Figure 3C). To further ensure production of soluble HLA-G, we
also tested the supernatants of the stimulated cells by enzyme-
linked immunosorbent assay (ELISA). CD4 HLA-Gpos T cells
showed production of soluble HLA-G, whereas HLA-G–negative
Tcells had only little sHLA-G in their supernatants, suggesting that
HLA-G5 is retained intracellularly in cells not bearing the mem-
brane-bound form of HLA-G at the same time (Figure 3D). As a
positive control, we used LCL-HLA-G1 and Hela-HLA-G5 trans-
fectants. To assess production of cytokines, puriﬁed CD4 HLA-
Gpos or HLA-Gneg T cells were independently stimulated with
anti-CD3/CD28 beads for 24 hours and the production of IFN-,
IL-10, and TGF- was determined by quantitative real-time PCR
(qRT-PCR). Four of 5 experiments showed reduced mRNA levels
for IFN- in the CD4 HLA-Gpos cells (2.4- to 20-fold; n  5)
compared with their negative counterparts. Similarly, IL-10 mRNA
Figure 1. Frequencies and phenotype of HLA-Gpos T cells in
peripheral blood. (A) FACS staining of peripheral blood lymphocytes
from healthy donors for HLA-G on CD4 and CD8 lymphocytes. Gates
for CD4 and CD8Tcells were set on FSC/CD4 and FSC/CD8 dot blots
to identify the desired subsets. HLA-G expression (bottom panel) was
assessed in comparison with the control isotype staining (top panel).A
representative staining is shown. (B) Percentages of HLA-Gpos T cells
in the CD4 or CD8 subpopulations of healthy volunteers (mean and
SD).
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polyclonal stimuli. (A) Isolation of CD4 HLA-Gpos T cells by sequential magnetic-
activated cell sorting (MACS) bead separation and analysis of the different steps of
the isolation by ﬂow cytometry. From top to bottom, dot plots show staining for whole
PBMCs before separation, puriﬁed CD4Tcells, the CD4 HLA-GnegT-cell fraction, and
the CD4 HLA-Gpos T-cell fraction. Counterstaining for CD14 indicates that there are
no contaminating monocytes in the preparation. (B) MACS-sorted CD4 HLA-Gneg and
HLA-Gpos T cells were cultured without stimulus for 72 hours to assess HLA-G
expression over time. Ex vivo expression of CD4 HLA-Gpos T cells was set as
reference. Graph shows summary of 3 experiments. (C) After MACS sorting, whole
CD4 (Œ), CD4 HLA-Gpos (F), and CD4 HLA-Gneg T cells (■) were stimulated with
allogeneic mature DCs at different ratios and proliferation was determined by [3H]
incorporation after 4 days. (D) Whole CD4 ( ), CD4 HLA-Gpos ( ), and CD4
HLA-Gneg ( ) T cells were isolated and stimulated with anti-CD3/CD28 beads.
Proliferation was determined after 4 days by [3H] incorporation. (E) CD4 HLA-Gpos
( ) and CD4 HLA-Gneg ( ) T cells were isolated and stimulated with mature
allogeneic DCs in the presence or absence of 500 U/mL IL-2. Proliferation was
determined after 4 days. (F) CD4 HLA-Gpos ( ) or CD4 HLA-Gneg T cells ( )
were stimulated for 4 days with allogeneic PBMCs and restimulated again with
PBMCs (allo MLR, left) or CD3/CD28 beads (right). Proliferation was determined 3
days later.Arepresentative experiment (1 of at least 3) is shown for panels C-F. Error
bars indicate standard error of the mean (SEM).
Figure 3. HLA-G production and cytokine proﬁle of CD4 HLA-Gpos and CD4 HLA-Gneg
T cells. (A) Separation of CD4 T-cell subpopulation by FACS sorting. After exclusion of
aggregated cells (SSC-Aversus SSC-W), the gate for CD4 T cells was set on FSC/CD4 dot
blottoidentifythedesiredsubsets.Forsorting,theHLA-G–positivepopulationwasassessed
compared with the control isotype staining; a second gate was set on HLA-G–negative cells.
One representative FACS sort experiment is shown. Values indicate the percentage of cells
in gates. (B) Ex vivo expression of HLA-G mRNA in FACS-sorted cells. JEG3 mRNA was
used as positive control. A representative experiment (1 of 5) is shown. (C) Intracellular
expression of HLA-G5 by intracellular staining for the soluble isoform HLA-G5 in sorted
HLA-G–positive and negative cells was performed after 4-day stimulation with CD3/CD28
beads using monoclonal antibody 5A6G7.Agate for CD4 T cells was set on FSC/CD4 dot
blot to identify the desired subset. HLA-G5 expression (lower panel) was assessed in
comparison with the control isotype staining (top panel). A representative staining is shown.
Values indicate the percentage of cells in gates. (D) Production of soluble HLA-G. Superna-
tants of CD3/CD28-stimulated HLA-G–positive and negative subsets were tested by ELISA
for soluble HLA-G. Cell lines transfected with either HLA-G1 or HLA-G5 were used as
positive controls. One representative experiment is shown. (E) Cytokines assessed by
RT-PCR are IFN- (left), IL-10 (middle), and TGF- (right). Graphs show results of 5
experiments. Error bars indicate standard deviation. (F) Cytokine production of puriﬁed
subsets. CD4 HLA-Gpos and HLA-Gneg T cells were stimulated with CD3/CD28 beads for 24
hours. Supernatants were assessed for cytokine production using the RayBio array. A
representativecytokineproﬁleforCD4HLA-Gneg(left)andforCD4HLA-Gpos(right)isshown.
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8.7-fold). For TGF- mRNA, only marginal differences were seen
(Figure 3E). In addition, supernatants of anti-CD3/CD28–
stimulated CD4 HLA-Gpos or HLA-Gneg T cells were tested for
cytokine production using a cytokine array. In good correlation
with the mRNAdata, in all arrays performed CD4 HLA-GposTcells
showed decreased production of IFN- and IL-10 protein. No
constant differences were found for other cytokines measured
(Figure 3F).
HLA-Gpos T cells are suppressive
Given the inhibitory role of HLA-G, we wondered if these cells
might have a suppressive effect on lymphocyte proliferation. To
investigate this possibility, we used a suppression assay where
proliferation of CFSE-labeled CD4 HLA-Gneg T cells was assessed
by ﬂow cytometry in the presence or absence of different ratios of
autologous CD4 HLA-Gpos T cells. This assay was ﬁrst established
and validated using puriﬁed CD4CD25high cells, where autolo-
gous suppression was used to evidence their suppressive properties
(data not shown). Addition of CD4 HLA-Gpos T cells led to a
signiﬁcant reduction of proliferation of CFSE-labeled CD4 HLA-
Gneg T cells (Figure 4A). Suppression was dependent on the
suppressor to responder ratio and ranged between 20% and 90% at
1:1 ratio (mean  58%; n  8), depending on the donor. To
investigate potential suppressive capacity of CD8 HLA-Gpos
T cells, we performed identical suppression experiments as described
for the CD4 HLAG cells, this time using puriﬁed CD8 HLA-Gneg
T cells as responder cells and CD8 HLA-Gpos T cells as suppres-
sors. Again, we observed a signiﬁcant suppression of proliferation
(Figure S2B). Moreover, when incubating CD8 HLA-Gpos T cells
as suppressors with CD4 HLA-Gneg T cells as responders and vice
versa, both CD4 and CD8 HLA-Gpos T cells were able to suppress
the opposite T-cell subpopulation (data not shown).
To exclude that CD4 HLA-Gpos T cells are identical to naturally
occurring CD4CD25 Tregs, we checked for the coexpression of
CD25, the forkhead transcription factor 3 (FOXP3), and HLA-G on
freshly isolated PBMCs. CD4 HLA-GposTcells show expression of
neither CD25 on the surface nor intracellular FOXP3 protein
(Figure 4B). Moreover, the levels of FoxP3 RNA did not differ
between CD4 HLA-Gpos and HLA-Gneg T cells, though CD4
CD25 Tregs showed high levels as expected (Figure 4C). Of note,
suppressive function of CD4 HLA-Gpos cells was demonstrated by
cells isolated both by magnetic bead isolation as well as by
ﬂow-cytometry sorting (data not shown). Furthermore, we demon-
strated suppressive function of CD4 HLA-Gpos cells also on
antigen-speciﬁc T cells. CD4 HLA-Gneg T cells were stimulated
with GA (glatirameracetate; 40 and 100 g/mL) in the absence of
allogeneic antigen-presenting cells (APCs). Here proliferation was
also suppressed by CD4 HLA-Gpos T cells (data not shown).
Suppression by CD4 HLA-Gpos T cells is reduced after
neutralization of HLA-G and is not dependent on cell contact
To test the hypothesis that HLA-G is not just the phenotypic marker
of a regulatory population but also mediates suppression, we ﬁrst
tried to rescue proliferation of the CD4 HLA-Gneg T cells by
neutralizing HLA-G with an anti–HLA-G blocking antibody
(mAb87G). mAb87G recognizes transmembraneous HLA-G1 as
well as soluble HLA-G5, which represent the 2 major HLA-G
isoforms. HLA-G neutralization partially antagonized suppressive
effects, leading to a 30% to 70% reduction of suppressive capacity
of the CD4 HLA-Gpos T cells (average, 48.9%  21.7%; n  3;
Figure 5A). Our data therefore clearly suggest that HLA-G largely
contributes to the suppressive effect of the CD4 HLA-Gpos T cells.
To assess whether direct cell to cell contact is essential for the
suppressive function of the CD4 HLA-Gpos T cells, we performed
the suppression assays in a transwell system, where responder and
suppressor cells were not in direct contact. Basically, suppression
was maintained when comparing proliferation rates with or without
cell-cell contact (Figure 5B). To further investigate if suppressive
capacity of CD4 HLA-Gpos T cells is dependent on soluble
factors, we collected supernatants from suppression assays and
transferred them to new proliferation assays of CFSE-labeled
CD4 HLA-Gneg T cells. Supernatants from assays performed in
the presence of CD4 HLA-Gpos T cells clearly suppressed T-cell
proliferation (mean  71.0%  17.40%), while control superna-
tants even enhanced proliferation compared with fresh medium
only (Figure 5C).
HLA-Gpos T cells are found in the human thymus
Our experiments show that HLA-G in HLA-Gpos T cells is stably
expressed on the protein and mRNA level and cannot easily be
induced by T-cell stimulation. However, this does not necessarily
imply that HLA-G expression is constitutive on a cell population,
since it still could be transiently induced by unknown stimuli in
vivo. However, an important hint that our population of HLA-Gpos
T cells represents a distinct cell population came from thorough
analysis of HLA-G expression on thymocyte subsets. FACS
analysis of HLA-G expression in freshly isolated thymocytes
(6 donors, ages 14 days to 1 year) showed that a small fraction of
single-positive CD4 (average, 1.0%; range, 0.6% to 1.5%) and
Figure 4. CD4 HLA-Gpos T cells have suppressor activity and they do not
express CD25 or FoxP3. (A) Suppression assay using CD4 HLA-Gpos T cells. CD4
HLA-Gpos T cells were titrated into CFDA-SE–labeled CD4 HLA-Gneg T cells cultured
in the presence of allogeneic PBMCs and soluble anti-CD3. Cell proliferation was
quantiﬁed by ﬂow cytometric assessment of CSFE dilution histograms on day 4. The
left panel compiles suppression capacity of CD4 HLA-Gpos T cells at different ratios in
3 independent experiments. The right panel shows a representative suppression
assay with percentages of proliferation stated in histogram. (B) FACS staining for
CD25/CD4/HLA-G at the cell surface (left) and intracellular ﬂow cytometry for
FOXP3/CD4/HLA-G (right). The dot plots show the staining on gated CD4 T cells;
values indicate the percentage of cells in gates. One representative experiment is
shown. (C) Expression of FoxP3 mRNAby CD4 HLA-Gpos/neg cells. FACS-sorted cells
(HLA-Gpos, HLA-Gneg, CD4CD25, and CD4CD25) from 2 different healthy
donors (light and dark bars) were analyzed for mRNA levels of Foxp3. Expression of
Foxp3 in PBMCs from one of the donors was used as calibrator ( 1).
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consistent and distinct expression of HLA-G (Figure 6), which was
comparable with the intensity of HLA-G expression on T cells in
peripheral blood. Double-positive thymocytes were devoid of
HLA-G, indicating that HLA-G expression is acquired after
positive selection and transition to the CD4 and CD8 single-
positive state, respectively. Thus, detection of HLA-G on thymo-
cytes strongly supports our assumption of HLA-Gpos T cells
representing a subset of cells belonging to the natural repertoire of
T cells.
HLA-Gpos T cells are present at sites of inﬂammation
Until now our data demonstrate the presence of HLA-Gpos T cells
with strong regulatory properties in peripheral blood of healthy
donors and in thymocytes.To investigate their putative role in vivo,
we looked for the presence of HLA-Gpos T cells at sites of
inﬂammation, such as the target organs in the inﬂamed nervous
system and in muscle disorders. We stained the cells in the
cerebrospinal ﬂuid (CSF) and peripheral blood of patients with
various inﬂammatory disorders (multiple sclerosis, MS, n  15;
other inﬂammatory neurologic diseases, OIND, n  10) and pa-
tients with noninﬂammatory neurologic diseases (NIND, n  9)
(Table S1). Patients with MS were separated in those having stable
disease and those experiencing an acute relapse. HLA-Gpos T cells
were detectable in the CSF of all 3 patient groups (Figure 7A;
Figure S3A). We observed signiﬁcantly higher frequency of CD4
HLA-Gpos T cells in the CSF of patients with acute inﬂammatory
disorders when compared with peripheral blood, while no statisti-
cally signiﬁcant differences were found in NIND and MS patients
for CD4 HLA-Gpos T cells (Figure 7B). No differences were
observed with regard to CD8 HLA-Gpos T cells in all 3 groups
(Figure S3B). No differences were observed in the frequencies of
HLA-G–positive CD4 and CD8 T cells in the blood of all 3 patient
groups; no statistical differences was found in comparison to
healthy donors. Interestingly, when MS patients were divided
according to their disease status, CD4 HLA-Gpos T cells were
slightly but signiﬁcantly increased in the CSF of patients with acute
relapse (Figure 7C). Again, no differences were found in the CD8
HLA-Gpos compartment (Figure S3C). Of note, the frequency of
HLA-Gpos T cells did not correlate with absolute cell counts in the
CSF. We next investigated muscle biopsy specimens from patients
with various inﬂammatory myopathies. Polymyositis (PM) and
inclusion body myositis (IBM) are putative autoimmune disor-
ders, where muscle ﬁbers are under attack of mainly cytotoxic
T lymphocytes.34 Muscle biopsy specimens from patients with
inﬂammatory myopathies (polymyositis, inclusion body myositis,
dermatomyositis, DM, n  5 each) were assessed for the coexpres-
sion of HLA-G and T-cell markers by double immunoﬂuorescence
staining.As expected, neither HLA-G immunoreactivity norTcells
inﬁltrates were detectable in sections of nonpathologic muscle
(data not shown). In inﬂammatory specimens, HLA-G was up-
regulated as described previously for muscle cells.26 Importantly,
some of the inﬁltrating or invading CD8 T cells showed expression
of HLA-G (Figure 7D), indicating that HLA-Gpos regulatoryTcells
may play a role in modulating muscle inﬂammation. Numbers of
detectable HLA-Gpos T cells correlated with the amount of cellular
inﬁltrates. No quantitative differences in frequency or topologic
distribution were found between PM, IBM, and DM.
Taken together, our data demonstrate that HLA-G–positive
T cells with putative regulatory function are found in the target
organs in patients with inﬂammatory disorders of the CNS or
muscle. The correlation of HLA-G T cells with acute CNS
inﬂammation (eg, MS relapse) supports the assumption of their
Figure 6. HLA-Gpos T cells are present in the human thymus in mature CD4 and
CD8 subsets. FACS analysis of HLA-G expression in thymocyte subsets: Thymo-
cytes were stained for CD4, CD8 and HLA-G. Gates were set on CD4CD8 and
CD4CD8 single-positive thymocytes as well as on double-positive thymocytes.
The percentage of HLA-Gpos cells was assessed in comparison with a negative
control. The summary of 6 independent stainings is shown. Horizontal bars indicate
the mean of 6 samples; vertical bars show SEM.
Figure 5. HLA-G–mediated suppression is reversed after neutralization of
HLA-G and independent of cell-cell contact. (A) Suppression assay at a ratio of
1:1 HLA-Gpos to CFDA-SE–labeled HLA-Gneg CD4Twas performed in the absence of
antibody (second panel), in the presence of an IgG isotype control (third panel), and
in the presence of anti–HLA-G1/5 blocking antibody (87G; fourth panel). Proliferation
was measured by ﬂow cytometry at day 4. (B) Suppression assay at a ratio of 1:1
HLA-Gpos to CFDA-SE–labeled HLA-Gneg CD4Twas performed either conventionally
or in a transwell chamber: CFDA-SE–labeled CD4 HLA-Gneg T cells were placed in
the lower chamber while CD4 HLA-Gpos were added to the upper chamber with no
cell-cell contact to CD4 HLA-Gneg responder cells (ratio 1:1). Proliferation of
CFDA-SE–labeled cells was measured by FACS. Graphs in panels A-B show
representative experiments reproduced at least 3 times. (C) Supernatants of
suppression assays with a CD4 HLA-Gneg/CD4 HLA-Gpos ratio of 1:1 (coculture) and
1:0 (control) were transferred to new proliferation assays of CFDA-SE–labeled CD4
HLA-Gneg T cells. Suppressive activity of supernatant was measured after 4 days by
FACS analysis. Graph shows summary of 6 independent experiments. Error bars
indicate standard deviation.
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Discussion
In this study, we identiﬁed and characterized 2 subsets of T cells
thatconstitutivelyexpresstheimmune-tolerogenicmoleculeHLA-G
on the cell surface. Both, CD4 HLA-Gpos and CD8 HLA-Gpos
T cells exist in the peripheral blood of healthy volunteers as small
subsets, which are able to suppress immune responses in vitro and
were found at sites of inﬂammation in vivo. RegulatoryTcells, also
referred to as suppressor T cells, are important mediators of
immune tolerance and play a critical role in the control of
autoimmunity, transplantation, and tumor immune surveillance.4,35
Several populations of regulatory cells can be distinguished, most
importantly the naturally occurring CD4CD25 Tregs, which are
constitutively present in humans under normal conditions.36-37
Distinct from those are the induced regulatory T cells, which
appear under certain conditions of tolerization, such as Tr1 cells.5
Furthermore, cells with regulatory properties are found within the
populations of CD8CD28 cells, TCR  cells, and CD4CD8
T cells.7,38-39 Albeit the importance of these populations is evident,
their study is difﬁcult due to the lack of cell surface marker(s)
sufﬁcient to deduce an attributed immune-suppressive or regula-
tory function per se. Our population of T cells is characterized by
the expression of the immune-tolerogenic molecule HLA-G on the
cell surface. Phenotypical analysis of the HLA-Gpos CD4 T cells
revealed a cytokine proﬁle that differs from Th1, Th2, Th3, or Tr1
cells.40-41 CD4 HLA-Gpos T cells, in contrast to most other
regulatory T cells, do not produce increased levels of IL-10 or
TGF-, the cytokines that have been mostly attributed with
regulatory functions. Reduced production of IFN-, however,
could indicate a nonproinﬂammatory nature of the CD4 HLA-Gpos
Tcells (Figure 3). Similar to the CD4CD25Tregs,36-37 HLA-Gpos
T cells show reduced proliferation to several stimuli. However, in
contrast to CD4CD25 Tregs, this hypoproliferation cannot be
overcome by the addition of exogenous IL-2 (Figure 2).
CD4 HLA-Gpos as well as CD8 HLA-Gpos T cells exert strong
suppression (20%-90% at 1:1 ratio; Figure 4 and Figure S2B),
which could partially be antagonized by blocking HLA-G with a
neutralizing antibody (mAb 87G). Suppression of HLA-Gpos
T cells was not depending on cell contact, as we could show using
transwell experiments and transfer of supernatants in the suppres-
sion experiments (Figure 5). It is therefore assumed that HLA-G is
a key molecule characterizing phenotype and function of the
Figure 7. HLA-G T cells are present in sites of neuroinﬂammation and inﬂammatory myopathies. (A) FACS analysis of paired blood and CSF specimens from patients
with and without neuroinﬂammatory diseases was performed. Gates for CD4 lymphocytes were set on CD4/FSC dot blots, and the percentage of HLA-Gpos cells was
assessed in comparison with a negative control.Arepresentative staining of 1 patient is shown. (B) Summary of paired samples of blood and CSF specimens for CD4 HLA-Gpos
T cells from NIND (left), OIND (middle), and MS (right) patients. Mean with SEM for each patient group is shown in upper panel; single pairing of blood-CSF samples for each
patient is shown in lower panel. (C) Comparison of CD4 HLA-Gpos T-cell percentages of MS patients in acute or stable phase of the disease.Again mean with SEM is shown in
upper panel; lower panel shows single patient pairing. (D) Consecutive cryosections of muscle from patients with polymyositis were stained with the HLA-G–speciﬁc mAb 87G,
the CD8 mAb B9.11 either as single staining (left column) or as double immunoﬂuorescence. Besides some muscle ﬁbers (asterisk), part of the CD8 T cells (arrowhead and
arrows), found to surround or even invade muscle ﬁbers, also stains positive for HLA-G. Original magniﬁcations: HLA-G single staining: (magniﬁcation  250); CD8 single
staining and CD8/ HLA-G double staining: (magniﬁcation  500). Sections were analyzed using anAxiophot 2 microscope (Zeiss, Oberkochen, Germany).
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suppressive properties, which are exerted by interaction with
differentinhibitoryreceptorseitherastransmembraneousorsoluble
isoforms.42-43 The identiﬁcation of a small subpopulation of T cells
expressing HLA-G now allows the identiﬁcation of a regulatory
T-cell subset by a well-deﬁned cell surface marker that at the same
time seems to represent the tolerogenic “player.”This allows the ad
hoc identiﬁcation of a regulatory T-cell subset by an unambiguous
marker indicating suppressive function. Our experiments show that
expression of the main transmembraneous isoform HLA-G1 is
virtually always accompanied by the expression of soluble iso-
forms, namely HLA-G5. Furthermore, HLA-G1 can be shed and
therefore can act as soluble HLA-G. However, both isoforms have
similar suppressive functions.17,44 Thus, it is reasonable to argue
that both transmembraneous as well as soluble HLA-G (iso) forms
contribute to the suppression. The exact cellular and molecular
mechanisms how HLA-Gpos T cells exert autologous immune
suppression remain elusive at present. One hypothesis is that
suppressive function is mediated by HLA-G that directly interacts
with respective receptors on HLA-G–negative T cells. The only
described HLA-G receptor present on T cells is ILT-2 (CD85j,
LIR-1), thus making this immunoglobulin-like transcript a possible
candidate underlying the molecular interaction of HLA-G–
mediatedT-cell suppression. HLA-G–positive cells could induce or
trigger HLA-G–negative cells to promote anti-inﬂammatory or
antiproliferative cytokine milieu. These changes might contribute
to the production of “suppressive” soluble factors, which might
include more than HLA-G.
What might be the role of HLA-G regulatory cells in vivo?
Although much knowledge has been accumulated concerning the
generation and functional properties of Tregs, less attention has
been paid to the key question of where the immune regulation by
Tregs may take place in vivo. Regulatory T cells can inhibit both
the priming and the effector phase of an immune response, so
suppression might occur both within lymphoid tissues and at
peripheral sites during immune reactions. Therefore HLA-Gpos
regulatory T cells could play a role in the mechanisms of central
and peripheral tolerance. In the thymus thymic epithelial cells are
capable of expressing HLA-G.45 We demonstrate here HLA-G
expression on a subset of single-positive CD4 and CD8 thymo-
cytes, but not in their double-positive precursors. Although we
cannot discard that some peripheral HLA-Gpos T cells recirculate
into the thymus, given the small percentages present in the
periphery of healthy humans and the lack of speciﬁc migration
markers, we favor the hypothesis that this population originates in
the thymus and the expression of HLA-G is acquired during
maturation. Our HLA-G–positive T cells express HLA-G protein
and RNA, indicating endogenous HLA-G production. Together
withourﬁndingofHLA-GregulatoryTcellsintheperipheryofhealthy
adult volunteers under physiologic conditions, it is reasonable to
postulate a role of HLA-Gpos T cells in the maintenance of peripheral
tolerance. However, HLA-Gpos regulatory T cells might also play an
important role in the regulation of peripheral inﬂammation. Ectopic
HLA-G expression or induction of HLA-G on immune cells has been
documented in a variety of pathologic conditions, namely autoimmune
or infectious inﬂammation,26,31,34,46-47 transplantation, and neoplastic
transformation.22-23,48-51 We found HLA-Gpos T cells in the target organs
ofpatientswithneuroinﬂammatorydisorders,aswellasinthemusclein
idiopathic myositis (Figure 7; Figure S3). The frequency of CD4
HLA-G regulatory T cells was signiﬁcantly elevated in the CSF from
patientswithacuteMSrelapsesandinpatientswithacuteneuroinﬂamam-
tory disorders such as vasculitis, encephalitis, or meningitis, whereas
CD8 HLA-Gpos T cells were found at sites of muscle inﬂammation.
Similarly, HLA-G–expressing T cells had been found in patients who
underwent transplantation and in HIV-infected patients.30-31 It is there-
fore conceivable that these suppressive T-cell populations migrate to or
are selectively attracted to the sites of inﬂammation to combat the
destructive events, and thus the study of HLA-G–positive T cells and
their relevance at target organs of inﬂammation become interesting. Of
note, HLA-Gpos T cells are detectable at low frequencies also in
CSF from patients even without an accompanying inﬂammatory or
structural damage (eg, patients with headache or pseudotumor
cerebri).Thus it is tempting to speculate that HLA-GposTcells may
play a role in CNS immune surveillance. It remains to be
determined how the population of HLA-Gpos regulatory T cells
contributes to lesion pathogenesis in acute and chronic MS or to
muscledamageinmyositis.However,theideaoflocalimmunosup-
pression by functional regulatory T cells modulating disease
activity and progression is appealing from an immunopathogenetic
as well as from a therapeutic view.52 There is evidence that T cells
including regulatory cells in the CNS may also provide beneﬁcial
effects in neuroinﬂammation. This view evolved from work
demonstrating the expression of neurotrophic factors byTcells and
in the CNS,53-54 the protective function of autoreactive T cells in
neuroinﬂammation,55 and the contribution of CD4CD25 Tregs
in recovery and protection from autoimmune encephalomyelitis.56
This could indeed be the case in humans, because HLA-G–
expressing T cells tend to accumulate in the cerebrospinal ﬂuid of
patients with inﬂammatory neurologic disease or migrate to points
of muscle inﬂammation in PM to counteract detrimental immune
responses. Not mutually exclusive to the hypothesis of migration or
attraction of HLA-G regulatory cells to sites of peripheral inﬂam-
mation,57 HLA-Gpos regulatory T cells could also be generated at
the sites of inﬂammation, for instance after acquiring HLA-G via
trogocytosis from donor cells,58 or as it has been shown for
CD4CD25hi FOXP-3 regulatory T cells in EAE (experimental
autoimmunce encephalomyelitis).59 Hereby they would balance
levels of peripheral immune reactions. Concerning their putative
role in maintaining peripheral immune tolerance, it is yet to be
determined whether the function of our HLA-G T regulatory cells
is impaired in autoimmune conditions, as it has been described for
CD4CD25 Tregs in MS.60-61 Of note, no orthologues of HLA-G
have been identiﬁed in other species, prohibiting in vivo experi-
ments on the role of HLA-G regulatory T cells in animals.
The identiﬁcation of a novel population of CD4 and CD8Tcells
characterized by the cell surface expression of HLA-G with
regulatory properties may have implications for the mechanisms of
inﬂammation, autoimmunity, and also tumor immune surveillance.
We believe that these cells belong to the physiological repertoire of
suppressor T cells, which putatively are important to maintain
immune tolerance.
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